In 2010, the ministry of health and other three departments jointly issued by the pharmaceutical industry structure adjustment on speeding up the guiding opinion on consolidation in the industry, made clear the direction, and adjust the structure of the organization's specific goals. For the present situation of Chinese medicine industry mergers and opportunity, the greater China region famous venture investment and private equity research institutions qing families research center released recently in 2010 "Chinese medicine industry analysis of m&a opportunity project that policy has become quite a push, push pharmaceutical industry to the historical opportunity of great integration. Pharmaceutical company merger, and constantly climax "bigger" is the pharmaceutical industry restructuring m&a in the future a period of time inside of persistent theme.

Pharmaceutical industry is high technology, high risk, high investment, high return of industry, is also industrialization of the high concentration of industries. Pharmaceutical industry to the overall production process is divided into industrial chain, circulation and consumptive link. Specific include medicinal plant, raw materials processing, product research and development, the production and circulation of business, health care, and other different fields. Currently in production areas, China has about 4000 home GMP pharmaceutical enterprise; In circulation, about 1 wholesale enterprise, more than 100000 retail enterprise, and more than 13000 medical logistics enterprise; In consumptive link, about 3 of a medical institution. The pharmaceutical industry and chemical raw materials and chemical preparation is divided into medicine, Chinese medicine yinpian, traditional Chinese medicine and biological pharmaceutical DengZi industry. The pharmaceutical industry value chain generally consists of four parts: the technical research and development, clinical trials, the production processing, sold. The traditional large pharmaceutical enterprise its production and business operation activities generally cover the value chain all four part 1. Read merger one of biological pharmaceutical field widely paid:

(1) high earnings growth star

Biotechnology is the world's fastest-growing one of high technology. All kinds of new biological technology has been widely used in medical care, agriculture, biological processing, resource development and utilization, and the pharmaceutical industries of development have a profound effect. Biological pharmaceutical industry is to use modern biological technology (including genetic engineering, cellular engineering, enzyme engineering, microbial engineering, biochemical engineering and protein engineering) production of drug industry. Biological pharmaceutical industry is a growth industry of high earnings. In 2009 China biological medicine industry scale reached 85 billion yuan, a year-on-year increase of 24.6%. And with more and more biological drugs into the health care, as well as national directory speed up innovation medicine research and development of the pace, the expected future biological pharmaceutical can industrial output will continue to rise.

At present the country by increasing investment to expand to the biological pharmaceutical industry research and development and the innovation ability so as to promote the development of biological industry. In "1025" programming, China will further promote with independent intellectual property rights of the biological technology industrialization, promote the biological industry cluster, and international development. Biological pharmaceutical safety manufacturing standard, improve supervision also step by step, this will cause the whole industry reshuffle acceleration, the policy of gradually improve industry concentration degree. As biological pharmaceutical fields in the world of booming development, make more and more multinational pharmaceutical company will look and energy into the field, and began to explore biological system in 2010, China's health ministry of three departments jointly issued by the pharmaceutical industry structure adjustment on speeding up the guiding opinion on consolidation in the industry, made clear the direction, and adjust the structure of the organization's specific goals. For the present situation of Chinese medicine industry mergers and opportunity, the greater China region famous venture investment and private equity research institutions qing families research center released recently in 2010 "Chinese medicine industry analysis of m&a opportunity project that policy has become quite a push, push pharmaceutical industry to the historical opportunity of great integration. Pharmaceutical company merger, and constantly climax "bigger" is the pharmaceutical industry restructuring m&a in the future a period of time inside of persistent theme.

Pharmaceutical industry is high technology, high risk, high investment, high return of industry, is also industrialization of the high concentration of industries. Pharmaceutical industry to the overall production process is divided into industrial chain, circulation and consumptive link. Specific include medicinal plant, raw materials processing, product research and development, the production and circulation of business, health care, and other different fields. Currently in production areas, China has about 4000 home GMP pharmaceutical enterprise; In circulation, about 1 wholesale enterprise, more than 100000 retail enterprise, and more than 13000 medical logistics enterprise; In consumptive link, about 3 of a medical institution. The pharmaceutical industry and chemical raw materials and chemical preparation is divided into medicine, Chinese medicine yinpian, traditional Chinese medicine and biological pharmaceutical DengZi industry. The pharmaceutical industry value chain generally consists of four parts: the technical research and development, clinical trials, the production processing, sold. The traditional large pharmaceutical enterprise its production and business operation activities generally cover all the four parts of the value chain.